StockData

Elutia vs Lineage Cell Therapeutics

ELUT and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELUT and LCTX compare

Lineage Cell Therapeutics is the larger company, worth 5.5 times as much as Elutia ($201M against $36.4M).

Lineage Cell Therapeutics grew revenue faster over the last twelve months (19.9% versus −0.34% for Elutia).

Elutia keeps more of each dollar of sales as profit, with a net margin of 427% compared with −247% at Lineage Cell Therapeutics.

Elutia scores higher on the StockData Score (9 against 8 for Lineage Cell Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELUTLCTX
Size and price
Market cap$36.4M$201M
Share price$0.823$0.795
Change, 1 year10.8%−55.8%
Change, 5 years−84.2%−60.0%
Beta (5Y)0.431.21
Employees2677
StockData Score
Total score9 (better)8
Valuation score1 (better)0
Growth score11
Performance score22
Health score55
Dividend score00
Valuation
P/S3.0× (better)15.4×
P/B2.3× (better)3.3×
FCF yield−126%−12.1% (better)
Fair value$0.923$0.657
Margin of safety10.8% (better)−21.0%
Growth
Revenue growth (TTM)−0.34%19.9% (better)
Revenue growth, 5Y average−22.0%51.5% (better)
Profitability
Gross margin57.8%–
Operating margin−215%−205% (better)
Net margin427% (better)−247%
FCF margin−379%−186% (better)
Return on equity–−59.0%
Return on invested capital–−262%
Financial health
Debt / equity0.000.00
Current ratio1.776.61 (better)
Altman Z-score−6.60−3.80 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.8%46.1%
Held by insiders52.0%74.4%
Insider net buying, 12 months$212K (better)$24.4K
Short interest, % of float0.16%37.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.